T1	Participants 541 617	five cohorts comprising 40 individuals with a single administration of A4250
T2	Participants 657 738	and three cohorts comprising 24 individuals with a 1-week administration of A4250
T3	Participants 1772 1817	of benefit to patients with cholestatic liver
